NPJ breast cancer

Keyphrases

Publications

volume 9, number 1, 2023

Shivangi Yadav, Ranya Virk, Carolina H Chung, Mariana Bustamante Eduardo, David VanDerway, Duojiao Chen, Kirsten Burdett, Hongyu Gao, Zexian Zeng, Manish Ranjan, Gannon Cottone, Xiaoling Xuei, Sriram Chandrasekaran, Vadim Backman, Robert Chatterton, Seema Ahsan Khan, Susan E Clare
Author Correction: Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer. NPJ breast cancer 9 (1) (2023)
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto D'amico, Pierfranco Conte, Valentina Guarneri
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. NPJ breast cancer 9 (1) (2023)
Véronique Debien, Alex De Caluwé, Xiaoxiao Wang, Martine J Piccart, Vincent K Tuohy, Emanuela Romano, Laurence Buisseret
Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ breast cancer 9 (1) (2023)
Ahmed M Alaa, Adrian L Harris, Mihaela van der Schaar
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Giancarlo Pruneri, Daniele Lorenzini, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
The central role of pathology labs in breast cancer precision oncology: a call for action. NPJ breast cancer 9 (1) (2023)
Elisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Shayin V Gibson, Elena Tomás-Bort, Lucía Rodríguez-Fernández, Michael D Allen, Jennifer J Gomm, Iain Goulding, Ulrich Auf dem Keller, Andrea Agnoletto, Cathrin Brisken, Barrie Peck, Angus J Cameron, John F Marshall, J Louise Jones, Edward Philip Carter, Richard Philip Grose
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression. NPJ breast cancer 9 (1) (2023)
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Sheetal Parida, Sumit Siddharth, Yuqing Xia, Dipali Sharma
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer. NPJ breast cancer 9 (1) (2023)
Giancarlo Pruneri, Daniele Lorenzini, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
The central role of pathology labs in breast cancer precision oncology: a call for action. NPJ breast cancer 9 (1) (2023)
Shane R Stecklein, Bruce F Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M Staley, Qamar J Khan, Anne P O'Dea, Lauren E Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B Pathak, Andrew K Godwin, Priyanka Sharma
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ breast cancer 9 (1) (2023)
Gloria V Echeverria, Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B Redwood, Yan Jiang, Aaron McCoy, Amanda L Rinkenbaugh, Rosanna Lau, Alexander J Trevarton, Chunxiao Fu, Rebekah Gould, Elizabeth E Ravenberg, Lei Huo, Rosalind Candelaria, Lumarie Santiago, Beatriz E Adrada, Deanna L Lane, Gaiane M Rauch, Wei T Yang, Jason B White, Jeffrey T Chang, Stacy L Moulder, William Fraser Symmans, Susan G Hilsenbeck, Helen Piwnica-Worms
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ breast cancer 9 (1) (2023)
Ahmed M Alaa, Adrian L Harris, Mihaela van der Schaar
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Ahmed M Alaa, Adrian L Harris, Mihaela van der Schaar
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Elisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Shayin V Gibson, Elena Tomás-Bort, Lucía Rodríguez-Fernández, Michael D Allen, Jennifer J Gomm, Iain Goulding, Ulrich Auf dem Keller, Andrea Agnoletto, Cathrin Brisken, Barrie Peck, Angus J Cameron, John F Marshall, J Louise Jones, Edward Philip Carter, Richard Philip Grose
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression. NPJ breast cancer 9 (1) (2023)
Shayin V Gibson, Elena Tomás-Bort, Lucía Rodríguez-Fernández, Michael D Allen, Jennifer J Gomm, Iain Goulding, Ulrich Auf dem Keller, Andrea Agnoletto, Cathrin Brisken, Barrie Peck, Angus J Cameron, John F Marshall, J Louise Jones, Edward Philip Carter, Richard Philip Grose
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression. NPJ breast cancer 9 (1) (2023)
Véronique Debien, Alex De Caluwé, Xiaoxiao Wang, Martine J Piccart, Vincent K Tuohy, Emanuela Romano, Laurence Buisseret
Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ breast cancer 9 (1) (2023)
Shivangi Yadav, Ranya Virk, Carolina H Chung, Mariana Bustamante Eduardo, David VanDerway, Duojiao Chen, Kirsten Burdett, Hongyu Gao, Zexian Zeng, Manish Ranjan, Gannon Cottone, Xiaoling Xuei, Sriram Chandrasekaran, Vadim Backman, Robert Chatterton, Seema Ahsan Khan, Susan E Clare
Author Correction: Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer. NPJ breast cancer 9 (1) (2023)
Sheetal Parida, Sumit Siddharth, Yuqing Xia, Dipali Sharma
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer. NPJ breast cancer 9 (1) (2023)
Sunil S Badve
Artificial intelligence in breast pathology - dawn of a new era. NPJ breast cancer 9 (1) (2023)
Sheetal Parida, Sumit Siddharth, Yuqing Xia, Dipali Sharma
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer. NPJ breast cancer 9 (1) (2023)
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto D'amico, Pierfranco Conte, Valentina Guarneri
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. NPJ breast cancer 9 (1) (2023)
Gloria V Echeverria, Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B Redwood, Yan Jiang, Aaron McCoy, Amanda L Rinkenbaugh, Rosanna Lau, Alexander J Trevarton, Chunxiao Fu, Rebekah Gould, Elizabeth E Ravenberg, Lei Huo, Rosalind Candelaria, Lumarie Santiago, Beatriz E Adrada, Deanna L Lane, Gaiane M Rauch, Wei T Yang, Jason B White, Jeffrey T Chang, Stacy L Moulder, William Fraser Symmans, Susan G Hilsenbeck, Helen Piwnica-Worms
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ breast cancer 9 (1) (2023)
Gloria V Echeverria, Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B Redwood, Yan Jiang, Aaron McCoy, Amanda L Rinkenbaugh, Rosanna Lau, Alexander J Trevarton, Chunxiao Fu, Rebekah Gould, Elizabeth E Ravenberg, Lei Huo, Rosalind Candelaria, Lumarie Santiago, Beatriz E Adrada, Deanna L Lane, Gaiane M Rauch, Wei T Yang, Jason B White, Jeffrey T Chang, Stacy L Moulder, William Fraser Symmans, Susan G Hilsenbeck, Helen Piwnica-Worms
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ breast cancer 9 (1) (2023)
Tianyu Zhang, Tao Tan, Luyi Han, Linda Appelman, Jeroen Veltman, Ronni Wessels, Katya M Duvivier, Claudette Loo, Yuan Gao, Xin Wang, Hugo M Horlings, Regina G H Beets-Tan, Ritse M Mann
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion. NPJ breast cancer 9 (1) (2023)
Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, Ellis G Levine, Jingqin R Luo, Yu Tao, Jeremy Hoog, Marie L Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Michael D Iglesia, Cynthia X Ma
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ breast cancer 9 (1) (2023)
Albert Grinshpun, Sara M Tolaney, Harold J Burstein, Rinath M Jeselsohn, Erica L Mayer
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Elisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Sheetal Parida, Sumit Siddharth, Yuqing Xia, Dipali Sharma
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer. NPJ breast cancer 9 (1) (2023)
Cody Ramin, Ruth M Pfeiffer, Sharon Fan, Maeve Mullooly, Roni T Falk, Kristine Jones, Neil E Caporaso, Lisa Bey-Knight, Mark A Sak, Michael S Simon, David H Gorski, Haythem Ali, Peter Littrup, Neb Duric, Mark E Sherman, Gretchen L Gierach
Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy. NPJ breast cancer 9 (1) (2023)
Ahmed M Alaa, Adrian L Harris, Mihaela van der Schaar
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Cody Ramin, Ruth M Pfeiffer, Sharon Fan, Maeve Mullooly, Roni T Falk, Kristine Jones, Neil E Caporaso, Lisa Bey-Knight, Mark A Sak, Michael S Simon, David H Gorski, Haythem Ali, Peter Littrup, Neb Duric, Mark E Sherman, Gretchen L Gierach
Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy. NPJ breast cancer 9 (1) (2023)
Sheetal Parida, Sumit Siddharth, Yuqing Xia, Dipali Sharma
Author Correction: Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer. NPJ breast cancer 9 (1) (2023)
Shane R Stecklein, Bruce F Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M Staley, Qamar J Khan, Anne P O'Dea, Lauren E Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B Pathak, Andrew K Godwin, Priyanka Sharma
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ breast cancer 9 (1) (2023)
Shane R Stecklein, Bruce F Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M Staley, Qamar J Khan, Anne P O'Dea, Lauren E Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B Pathak, Andrew K Godwin, Priyanka Sharma
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ breast cancer 9 (1) (2023)
Shayin V Gibson, Elena Tomás-Bort, Lucía Rodríguez-Fernández, Michael D Allen, Jennifer J Gomm, Iain Goulding, Ulrich Auf dem Keller, Andrea Agnoletto, Cathrin Brisken, Barrie Peck, Angus J Cameron, John F Marshall, J Louise Jones, Edward Philip Carter, Richard Philip Grose
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression. NPJ breast cancer 9 (1) (2023)
Shane R Stecklein, Bruce F Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M Staley, Qamar J Khan, Anne P O'Dea, Lauren E Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B Pathak, Andrew K Godwin, Priyanka Sharma
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ breast cancer 9 (1) (2023)
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Véronique Debien, Alex De Caluwé, Xiaoxiao Wang, Martine J Piccart, Vincent K Tuohy, Emanuela Romano, Laurence Buisseret
Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ breast cancer 9 (1) (2023)
Sheetal Parida, Sumit Siddharth, Yuqing Xia, Dipali Sharma
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer. NPJ breast cancer 9 (1) (2023)
Sunil S Badve
Artificial intelligence in breast pathology - dawn of a new era. NPJ breast cancer 9 (1) (2023)
Sunil S Badve
Artificial intelligence in breast pathology - dawn of a new era. NPJ breast cancer 9 (1) (2023)
Albert Grinshpun, Sara M Tolaney, Harold J Burstein, Rinath M Jeselsohn, Erica L Mayer
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Tianyu Zhang, Tao Tan, Luyi Han, Linda Appelman, Jeroen Veltman, Ronni Wessels, Katya M Duvivier, Claudette Loo, Yuan Gao, Xin Wang, Hugo M Horlings, Regina G H Beets-Tan, Ritse M Mann
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion. NPJ breast cancer 9 (1) (2023)
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto D'amico, Pierfranco Conte, Valentina Guarneri
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. NPJ breast cancer 9 (1) (2023)
Giancarlo Pruneri, Daniele Lorenzini, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
The central role of pathology labs in breast cancer precision oncology: a call for action. NPJ breast cancer 9 (1) (2023)
Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, Ellis G Levine, Jingqin R Luo, Yu Tao, Jeremy Hoog, Marie L Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Michael D Iglesia, Cynthia X Ma
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ breast cancer 9 (1) (2023)
Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, Ellis G Levine, Jingqin R Luo, Yu Tao, Jeremy Hoog, Marie L Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Michael D Iglesia, Cynthia X Ma
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ breast cancer 9 (1) (2023)